HETERO LABS
GenericsHETERO LABS is a generic drug manufacturer focused on Dermatology, Cardiovascular, Infectious Disease.
HETERO LABS's Key Drugs
HETERO LABS's core commercial portfolio centers on AMLODIPINE BESYLATE AND VALSARTAN, spanning Dermatology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
HETERO LABS's Recent FDA Approvals
New NDA/BLA approvals for HETERO LABS over the last two years — novel drugs only, excluding generics and label supplements.
HETERO LABS's Therapeutic Areas
HETERO LABS's approved drugs and pipeline span 3 therapeutic areas, led by Dermatology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HETERO LABS's Top Competitors
HETERO LABS's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HETERO LABS Pipeline Snapshot
Active clinical trials for HETERO LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE BESYLATE AND VALSARTAN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-09-16
- Latest
- 2025-05-22
- Applications
- 8